Showing 1611-1620 of 2042 results for "".
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance for Pipeline Therapieshttps://modernod.com/news/agtc-formalizes-patient-advisory-council-to-provide-insights-and-guidance-for-pipeline-therapies/2478156/Applied Genetic Technologies Corporation (AGTC), announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the company’s culture and clinical and preclinical programs. Engagement with pa
- ImprimisRx’s Patented Klarity-C 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometristshttps://modernod.com/news/imprimisrxs-patented-klarity-c-0-1-cyclosporine-preservative-free-formulation-may-now-be-prescribed-by-floridas-2000-optometrists/2477907/ImprimisRx announced its Klarity-C preservative-free formulation (0.1% cyclosporine emulsion) may now be prescribed by Florida’s nearly 2,000 optometrists as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents. Klarity-C w
- Trump to Name Former GlaxoSmithKline Executive to Head “Warp Speed” Coronavirus Vaccine Effort: Reportshttps://modernod.com/news/trump-to-name-former-glaxosmithkline-executive-to-head-warp-speed-coronavirus-vaccine-effort-reports/2477765/According to White House officials cited in several reports Wednesday, President Donald Trump is expected to appoint Moncef Slaoui, the former chairman of GlaxoSmithKline’s vaccines division, as chief adviser of Operation Warp Speed, an initiative aimed at speeding up the search for a coron
- CRISPR And Spit Might Be Keys To Faster, Cheaper, Easier Tests For The Coronavirushttps://modernod.com/news/crispr-and-spit-might-be-keys-to-faster-cheaper-easier-tests-for-the-coronavirus/2477604/Being able to test for coronavirus infections is a critical component to reopening society—even a little bit—after the initial wave of COVID-19. So there is an urgent need for faster, cheaper tests than the ones available at present. According to an NPR
- Santen Forges Ophthalmology Partnerships With Verily and WHOhttps://modernod.com/news/santen-forges-ophthalmology-partnerships-with-verily-and-who/2477300/Santen has forged two separate partnerships with Google’s life sciences sister company Verily and the International Telecommunication Union (ITU), whose initiative is supported by the World Health Organisation (WHO), according to a
- Aerpio Pharmaceuticals Presents New Data Showing Potential of Topical Ocular Formulation of AKB-9778 When Combined with Prostaglandinhttps://modernod.com/news/aerpio-pharmaceuticals-presents-new-data-showing-potential-of-topical-ocular-formulation-of-akb-9778-when-combined-with-prostaglandin/2477289/Aerpio Pharmaceuticals announced that Kevin Peters, MD, Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a phase 1b trial showing the potential of a topical ocular formulation of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower IOP with minimal con
- Nicox Receives Formulation Patent Extending NCX 470 US Patent Coverage to 2039https://modernod.com/news/nicox-receives-formulation-patent-extending-ncx-470-us-patent-coverage-to-2039/2477270/Nicox has received approval from the U.S. Patent and Trademark Office of a formulation patent for NCX 470, extending the U.S. patent coverage to 2039. NCX 470, a novel second gener
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- IDx Taps Former LabCorp Executive to Lead Sales and Customer Successhttps://modernod.com/news/idx-taps-former-labcorp-executive-to-lead-sales-and-customer-success/2477030/IDx Technologies announced that it has appointed former LabCorp executive Seth Rainford as President of Global Markets. In his newly created role, Mr. Rainford will be charged with expanding market opportunities and driving operational excellence at IDx. “Se